Table 3.
The demographics and baseline characteristics of the patients
| Characteristics | Brolucizumab N = 56 | Aflibercept N = 58 | P value |
|---|---|---|---|
| Age, years | |||
| Mean ± SD | 72.05 ± 11.03 | 70.17 ± 9.02 | 0.32 |
| Median | 72.00 | 70.5 | |
| Min, max | 51.00, 91.00 | 54.00, 91.00 | |
| Sex, n (%) | 0.17 | ||
| Male | 37 (66.1) | 30 (51.7) | |
| Female | 19 (33.9) | 28 (48.3) | |
| LogMAR BCVA | |||
| Mean ± SD | 0.84 ± 0.32 | 0.87 ± 0.27 | 0.63 |
| Min, max | 0.28, 1.42 | 0.26, 1.30 | |
| CMT (µm) | |||
| Mean ± SD | 355 ± 89.7 | 365.5 ± 55.78 | 0.46 |
| Min, max | 211.00, 598.00 | 265.00, 566.00 | |
| Presence of IRF n (%) | 46 (82.1) | 44 (75.9) | 0.55 |
| Presence of SRF n (%) | 46 (82.1) | 48 (82.8) | > 0.99 |
| Presence of SHRM n (%) | 24 (42.9) | 31 (53.4) | 0.35 |
Data presented as mean ± standard deviation or n (%)
BCVA Best corrected visual acuity, CMT Central macular thickness, IRF intraretinal fluid, SRF subretinal fluid, SHRM subretinal hyper-reflective material, SD standard deviation
*p-value < 0.05 for the t-test considered significant (none of the t-test found significance)
#p-values < 0.05 for the chi-square test considered for significant correlation (none of the chi-square test found correlation)